Back to News
Jun 4, 2026 12:30 PM

Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies

WW International (NASDAQ:WW) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE:LLY) LillyDirect digital health care platform, expanding access to branded GLP-1 weight-loss medications alongside clinical and behavioral support services.

• Eli Lilly stock is surging to new heights today. What’s driving LLY stock higher?

Weight Watchers Expands GLP-1 Access Through LillyDirect

The addition to LillyDirect aligns with Weight Watchers' strategy to broaden access to GLP-1 treatments through its Med+ program, which provides patient support before, during and after treatment.

LillyDirect connects patients with independent care options, pharmacy fulfillment resources, and educational content as demand for GLP-1 medications continues to increase.

Weight Watchers said its Med+ offering complements these services with a comprehensive care model designed to support long-term weight management.

Ascidian, Eli Lilly Partner On RNA-Based Kidney Disease Therapies

Ascidian Therapeutics on Wednesday ...